For example, cetuximab and panitumumab target epidermal growth factor receptor (EGFR) to treat colorectal cancer (Braig et al., 2015), trastuzumab targets HER2 to treat breast cancer (Mayor, 2006), and rituximab targets CD20 to treat leucocythemia (Arzoo et al., 2002). This evidence concerns the gene ERBB2 and colorectal cancer.